Categories: AntibodiesBiotechDrugDiscoveryImmunotherapyOncology
Investors 1
Mentions in press and media 6
| Date | Title | Description |
| 21.04.2025 | Aethon Therapeutics to Share Preclinical and Discovery-Stage Updates on KRAS-G12C Hapten-Peptide Immunotherapies at AACR 2025 | New York, April 21, 2025 — Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, will present u... |
| 21.04.2025 | Aethon Therapeutics to Share Preclinical and Discovery-Stage Updates on KRAS-G12C Hapten-Peptide Immunotherapies at AACR 2025 | New York, April 21, 2025 — Aethon Therapeutics, Inc., a biotechnology company discovering and developing novel antibody therapeutics designed to attack cancer cells in tandem with targeted covalent inhibitor cancer therapies, will present u... |
| 04.04.2024 | Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs | Aethon will apply its proprietary HapImmune™ platform to create novel antibodies that home in on cancer neoantigens generated by treatment with RAS inhibitors
Collaboration focuses on key Revolution Medicines pipeline programs
NEW YORK, Apr... |
| 04.04.2024 | Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs | Aethon will apply its proprietary HapImmune™ platform to create novel antibodies that home in on cancer neoantigens generated by treatment with RAS inhibitors
Collaboration focuses on key Revolution Medicines pipeline programs
NEW YORK, Apr... |
| 09.01.2023 | ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells | Aethon’s HapImmune™ platform, described in a recent publication in the journal Cancer Discovery, unites immunotherapy and targeted therapy
$30M in Series A funding, with $25M from Apple Tree Partners (ATP) and participation by NYU Langone ... |
| - | Aethon Therapeutics | - |
Reviews 0
